A platform technology that detects misfolded biomarker proteins in body fluids to assess the risk of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and ALS years before symptoms appear.

A non-invasive test that uses the betaSENSE platform to detect early protein misfolding biomarkers in body fluids, enabling risk assessment for Alzheimer’s, Parkinson’s, and ALS up to 17 years before symptoms.